IP Library Granted Patent US 11,597,744
Granted Patent B2
US 11,597,744 · App. 16/627,091 · Granted Mar 7, 2023

Chiral phosphoramidite auxiliaries and methods of their use

Inventors: Sukumar Sakamuri (San Diego, CA); Curt W. Bradshaw (San Diego, CA); Dingguo Liu (San Diego, CA); Laxman Eltepu (San Diego, CA)
Assignee: SIRIUS THERAPEUTICS, INC.
C07H19/11C07H19/213C07H21/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,597,744
App. No.
16/627,091
Granted
Mar 7, 2023
Kind
B2
Abstract

Disclosed are chiral phosphoramidite auxiliary compositions for diastereoselective synthesis of stereochemically enriched oligonucleotides, and nucleoside phosphoramidite compounds comprising the same. Exemplary structures of the chiral phosphoramidite auxiliary compositions include Formulas (IA) and (IB).

Claims (46)

1. A compound of formula (IIIA) or (IIIB):

wherein

is a single carbon-carbon bond or a double carbon-carbon bond;

A is an optionally substituted C 1-12 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted C 3-10 cycloalkyl-C 1-6 -alkyl, optionally substituted C 1-9 heterocyclyl, optionally substituted C 1-9 heterocyclyl-C 1-6 -alkyl, sugar analogue, nucleoside, nucleotide, or oligonucleotide;

each of R 1 and R 2 is independently an optionally substituted C 1-6 alkyl or optionally substituted C 6-10 aryl, or R 1 and R 2 , together with the atoms to which each is attached, combine to form an optionally substituted 5- to 8-membered ring; and

each of R 3 and R 4 is independently H, optionally substituted C 1-6 alkyl, or optionally substituted C 6-10 aryl.

2. The compound of claim 1 , wherein R 1 and R 2 , together with the atoms to which each is attached, combine to form an optionally substituted 5- to 8-membered ring.

3. The compound of claim 1 , wherein the compound is of the following structure:

4. A nucleoside phosphoramidite comprising a sugar bonded to a nucleobase and to a phosphoramidite of the following structure:

wherein

is a single carbon-carbon bond or a double carbon-carbon bond;

each of R 1 and R 2 is independently an optionally substituted C 1-6 alkyl or optionally substituted C 6-10 aryl, or R 1 and R 2 , together with the atoms to which each is attached, combine to form an optionally substituted 5- to 8-membered ring; and

each of R 3 and R 4 is independently H, optionally substituted C 1-6 alkyl, or optionally substituted C 6-10 aryl.

5. The nucleoside phosphoramidite of claim 4 , wherein the nucleoside phosphoramidite is of the following structure:

wherein

B 1 is a nucleobase;

Y 1 is H or C 1-6 alkyl;

R 5 is H, O-protected hydroxyl, optionally substituted C 1-6 alkoxy, or halogen; and

R 6 is a hydroxyl protecting group.

6. The nucleoside phosphoramidite of any one of claims 5 , wherein R 6 is dimethoxytrityl.

7. The nucleoside phosphoramidite of claim 4 , wherein R 1 and R 2 , together with the atoms to which each is attached, combine to form an optionally substituted 5- to 8-membered ring.

8. The nucleoside phosphoramidite of claim 4 , wherein the phosphoramidite is of the following structure:

9. A method of preparing a composition comprising an oligonucleotide comprising a stereochemically enriched internucleoside phosphorothioate, the method comprising (i) reacting the nucleoside phosphoramidite of claim 4 with a coupling activator and a nucleoside comprising a 5′-hydroxyl or an oligonucleotide comprising a 5′-hydroxyl, (ii) reacting with an electrophilic source of acyl, and (iii) reacting with a sulfurizing agent to produce the oligonucleotide comprising a stereochemically enriched internucleoside phosphorothioate triester.

10. A method of preparing the nucleoside phosphoramidite comprising a sugar bonded to a nucleobase and phosphoramidite of the following structure:

wherein

is a single carbon-carbon bond or a double carbon-carbon bond;

each of R 1 and R 2 is independently an optionally substituted C 1-6 alkyl or optionally substituted C 6-10 aryl, or R 1 and R 2 , together with the atoms to which each is attached, combine to form an optionally substituted 5- to 8-membered ring; and

each of R 3 and R 4 is independently H, optionally substituted C 1-6 alkyl, or optionally substituted C 6-10 aryl;

the method comprising reacting a sugar bonded to a nucleobase with a compound of formula (VIIIA) or (VIIIB):

wherein

X is a halogen or pseudohalogen.

11. An oligonucleotide comprising one or more internucleoside groups independently selected from the group consisting of linkers of formulas (XIA), (XIB), (XIIA) and (XIIB):

where

is a single carbon-carbon bond or a double carbon-carbon bond;

each of R 1 and R 2 is independently an optionally substituted C 1-6 alkyl or optionally substituted C 6-10 aryl, or R 1 and R 2 , together with the atoms to which each is attached, combine to form an optionally substituted 5- to 8-membered ring;

each of R 3 and R 4 is independently H, optionally substituted C 1-6 alkyl, or optionally substituted C 6-10 aryl; and

R 7 is acyl.

12. The compound of claim 1 , wherein each of R 3 and R 4 is independently H.

13. The compound of claim 2 , wherein the optionally substituted 5- to 8-membered ring is an optionally substituted 6-membered carbocyclic ring.

14. The nucleoside phosphoramidite of claim 4 , wherein each of R 3 and R 4 is independently H.

15. The nucleoside phosphoramidite of claim 7 , wherein the optionally substituted 5- to 8-membered ring is an optionally substituted 6-membered carbocyclic ring.

16. The method of claim 10 , wherein the optionally substituted 5- to 8-membered ring is an optionally substituted 6-membered carbocyclic ring.

17. The method of claim 10 , wherein each of R 3 and R 4 is independently H.

18. The oligonucleotide of claim 11 , wherein the substituted 5- to 8-membered ring is substituted 6-membered carbocyclic ring.

19. The oligonucleotide of claim 11 , comprising one or more internucleoside groups independently selected from the group consisting of linkers of formulas (XIIA) and (XIIB):

20. The oligonucleotide of claim 11 , comprising one or more internucleoside groups independently selected from the group consisting of linkers of formulas (XIA) and (XIB):

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2022
From: SAKAMURI, SUKUMAR; BRADSHAW, CURT W.; LIU, DINGGUO; ELTEPU, LAXMAN
To: SOLSTICE BIOLOGICS, LTD.
Reel/Frame 060122/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2022
From: SOLSTICE BIOLOGICS LIMITED
To: CLEAR SKIES BIO LLC
Reel/Frame 060123/0004 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2022
From: CLEAR SKIES BIO LLC
To: SIRIUS THERAPEUTICS, INC.
Reel/Frame 060123/0482 →
Continuity (2)
Provisional Application 62527078 · Jun 30, 2017
Related Publication 20200140476A1 · May 7, 2020
Cited By (1)
US 12,269,839